JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Jazz Pharmaceuticals plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$208.43−1.80 (-0.86%)
Close on Oct 19, 2026
- Market cap
- $14.47B
- P/E (TTM)
- 14.3
- Dividend yield
- –
Jazz Pharmaceuticals plc revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $1.16B | $1.03B | $1.13B | $1.06B | $985.60M | $839.40M | $1.03B | $989.71M | $964.14M | $842.10M | $967.34M | $938.40M | 95.7% | +17.3% |
| Sleep | $501.70M | $439.40M | – | – | $450.70M | $382.00M | – | – | – | – | – | – | 41.5% | +11.3% |
| Xywav | $471.20M | $408.20M | $465.45M | $431.41M | $415.30M | $344.80M | $400.96M | $388.47M | $368.47M | $315.30M | $337.02M | $331.63M | 39.0% | +13.5% |
| Oncology | $362.30M | $333.40M | – | – | $274.70M | $229.40M | – | – | – | – | – | – | 30.0% | +31.9% |
| Epidiolex/Epidyolex | $292.10M | $249.80M | $287.12M | $302.61M | $251.70M | $217.70M | $275.05M | $251.56M | $247.10M | $198.72M | $240.62M | $213.71M | 24.2% | +16.1% |
| Epilepsy | $292.10M | $249.80M | – | – | $251.70M | $217.70M | – | – | – | – | – | – | 24.2% | +16.1% |
| Zepzelca | $105.80M | $101.00M | $90.44M | $79.30M | $74.50M | $63.00M | $78.33M | $85.84M | $81.05M | $75.10M | $74.01M | $77.99M | 8.8% | +42.0% |
| Rylaze/Enrylaze | $99.50M | $103.70M | $108.16M | $99.87M | $100.70M | $94.20M | $101.49M | $98.78M | $107.83M | $102.75M | $101.75M | $104.86M | 8.2% | -1.2% |
| Defitelio/defibrotide | $62.00M | $47.40M | $58.87M | $51.75M | $48.10M | $40.70M | $57.65M | $65.82M | $45.42M | $47.68M | $51.08M | $47.73M | 5.1% | +28.9% |
| Royalties and contract revenues | $52.20M | $43.60M | $65.48M | $61.70M | $60.10M | $58.40M | $62.96M | $65.26M | $59.68M | $59.88M | $44.60M | $33.74M | 4.3% | -13.1% |
| Modeyso | $48.20M | $41.40M | $36.54M | $11.03M | $500.00K | $0 | $0 | $0 | – | – | – | – | 4.0% | +9540.0% |
| High-sodium oxybate AG royalty revenue | $42.20M | $36.30M | $55.70M | $52.95M | $54.10M | $48.90M | $55.31M | $58.16M | $54.16M | $49.95M | $39.39M | $28.92M | 3.5% | -22.0% |
| Vyxeos | $31.40M | $26.60M | $34.73M | $37.58M | $44.90M | $29.50M | $53.25M | $34.31M | $43.01M | $32.02M | $46.91M | $29.83M | 2.6% | -30.1% |
| Xyrem | $30.50M | $31.20M | $37.78M | $35.66M | $35.40M | $37.20M | $49.29M | $58.11M | $62.18M | $64.23M | $106.72M | $125.11M | 2.5% | -13.8% |
| Ziihera | $15.40M | $13.30M | $8.54M | $8.31M | $6.00M | $2.00M | $1.05M | $0 | $0 | $0 | – | – | 1.3% | +156.7% |
| Other royalty and contract revenues | $10.00M | $7.30M | – | $8.75M | $6.00M | $9.50M | – | $7.11M | $5.52M | $9.93M | – | $4.82M | 0.8% | +66.7% |
| Other | $0 | $2.70M | $3.31M | $2.14M | $8.50M | $10.30M | $2.97M | $2.23M | $2.70M | $3.57M | $4.09M | $2.91M | 0.0% | -100.0% |
| Sunosi | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Sativex | – | – | $1.50M | $4.75M | $4.62M | $5.41M | $5.17M | $4.59M | $6.38M | $2.74M | $5.14M | $4.63M | – | – |
| Rylaze | – | – | – | – | – | – | – | – | – | – | $101.75M | $104.86M | – | – |
| Total Neuroscience | – | – | $791.86M | $774.43M | $707.02M | $605.19M | $730.47M | $702.72M | $684.14M | $580.98M | $689.50M | $675.08M | – | – |
| Total Oncology | – | – | $337.28M | $287.84M | $274.15M | $229.45M | $291.76M | $284.75M | $277.31M | $257.55M | $273.75M | $260.41M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.08B | $959.80M | $1.08B | $1.02B | $936.30M | $797.90M | $973.62M | $953.67M | $924.59M | $808.21M | $910.58M | $884.58M | 89.2% | +15.1% |
| Europe | $97.40M | $92.40M | $88.92M | $86.41M | $82.70M | $83.60M | $81.89M | $77.32M | $82.16M | $71.36M | $75.05M | $68.97M | 8.1% | +17.8% |
| All other | $33.00M | $16.70M | $32.69M | $19.23M | $26.70M | $16.30M | $32.67M | $23.98M | $17.07M | $22.41M | $26.31M | $18.59M | 2.7% | +23.6% |
From the segment and revenue-disaggregation notes of Jazz Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.